NitiNotes

Company Overview

Snapshot

Founded in July 2014 by Irit Yaniv and Tamir Wolf, NitiNotes operates with 11–50 employees. The company has raised $32.9M across 4 funding rounds from 5 investors. In August 2026, NitiNotes announced the activation of a clinical site at Weill Cornell Medicine and NewYork-PresbyterianWeill Cornell Medical Center for its EASE IDE trial, indicating significant progress in its clinical development and market expansion efforts.

Business overview

NitiNotes is a clinical-stage Health Tech & Life Sciences company focused on developing a revolutionary treatment for obesity. Its core product, the EndoZip, is an automated and operator-independent robotic suturing system designed to simplify and speed up endoscopic gastroplasty procedures. This minimally invasive solution aims to provide an effective treatment option for patients with obesity class I & II who are not candidates for traditional bariatric surgery, serving the medical devices and medical treatment & therapeutics sectors within the healthcare industry.

Strategic signal

NitiNotes received CE Mark approval for its EndoZip system in November 2025, marking a critical regulatory milestone. This approval validates the safety and efficacy of the first fully automated suturing system for endoscopic sleeve gastroplasty, signaling to investors a significant step towards commercialization and market entry in Europe. This development positions NitiNotes to address a substantial patient population with a novel, minimally invasive obesity treatment.

Company Intelligence Q&A

What is the primary product developed by NitiNotes?

NitiNotes develops the EndoZip, a fully automated endoscopic suturing system designed to simplify and speed up endoscopic gastroplasty procedures for obesity treatment.

When did NitiNotes receive CE Mark approval for its EndoZip system?

NitiNotes received CE Mark approval for its EndoZip system in November 2025, allowing for its marketing and use in Europe.

What significant clinical trial milestone did NitiNotes announce in August 2026?

In August 2026, NitiNotes announced the activation of Weill Cornell Medicine and NewYork-PresbyterianWeill Cornell Medical Center as a clinical site for its EASE IDE trial, evaluating the EndoZip Automated Suturing System.

Which investors participated in NitiNotes' SAFE round in December 2024?

In December 2024, NitiNotes closed a SAFE round with participation from investors including Elron Ventures.

When were the first commercial EndoZip procedures in Spain announced?

NitiNotes announced the first commercial EndoZip procedures in Spain in April 2026, following its CE-marked automated suturing system.